Disease, Pharmaceutical and Radiation - Diagnostic Imaging Brief

First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

Imaging Technology

AUGUST 29, 2023

Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.

Pharmaceutical

Pharmaceutical Radiopharmaceuticals Clinic Medical

GE HealthCare Closes MIM Software Acquisition

Imaging Technology

APRIL 2, 2024

announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. There is also special focus on radiation therapy and Theranostics.

Healthcare

Healthcare Healthcare Radiation Oncology Magnetic Resonance Imaging

NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

Imaging Technology

AUGUST 31, 2023

Ac-225 to Curadh for use in its pioneering molecularly targeted radiation (MTR) programs for the treatment of common lethal tumors. “We Ac-225 carries sufficient radiation to cause cell death in a localized area of targeted cells, while its half-life limits unwanted radioactivity in patients. actinium-225 (Ac-225).

Medical

Medical Radiopharmaceuticals Pharmaceutical Radiation

GE HealthCare Announces Agreement to Acquire MIM Software

Imaging Technology

JANUARY 8, 2024

Recognizing the industry transformation taking place as digital innovation reshapes the experience of patients and providers, GE HealthCare – a leading global medical technology, pharmaceutical diagnostics, and digital innovator – is focused on developing smart devices, aligned to disease states and enabled by digital.

Healthcare

Healthcare Healthcare Radiation Oncology Radiation

NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)

Imaging Technology

JULY 5, 2023

Nucleus will use NorthStar’s Ac-225 for their customers’ radioligand pharmaceutical programs. Ac-225 carries sufficient radiation to cause cell death in a localized area of targeted cells, while its half-life limits unwanted radioactivity in patients. NorthStar is positioned to be the first commercial-scale producer of n.c.a.

Medical

Medical Radiopharmaceuticals Pharmaceutical Radiation

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Imaging Technology

APRIL 3, 2023

This unit will enable us to develop and manufacture patient doses for pharmaceutical or biotechnology companies as well as share our radiopharmaceutical development and commercialization expertise with them where they may require additional infrastructure, resources or the specialized knowledge required for complex radiopharmaceutical development.

Medical

Medical Radiopharmaceuticals Pharmaceutical Radiation

Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

Imaging Technology

JULY 25, 2023

milla1cf Tue, 07/25/2023 - 20:22 July 25, 2023 — Ratio Therapeutics Inc.

Radiopharmaceuticals

Radiopharmaceuticals Imaging Pharmaceutical Disease

The rise of theranostics: Part 3 -- What is a theranostics center?

AuntMinnie

JUNE 3, 2024

Eliot Siegel, MD; Stanislav Spiridonov, MD; Nathan Gee, MD; and Anthony Chang, PhD, are among a niche gathering of early adopters, entrepreneurial physicians, medical physicists, and investors with a sweet spot for nuclear medicine, diagnostic radiology, and radiation oncology. led by Harshad Kulkarni, MD, as principal investigator.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology

First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

Imaging Technology

JULY 11, 2023

This partnership exemplifies our commitment to Find, Fight and Follow disease by delivering innovative solutions to improve cancer care, ultimately leading to better patient outcomes." milla1cf Tue, 07/11/2023 - 09:02 July 11, 2023 — Ratio Therapeutics Inc.

Radiopharmaceuticals

Radiopharmaceuticals Imaging Pharmaceutical Disease

AuntMinnie 2007: Gadolinium: A 'necessary factor' in the development of NSF?

AuntMinnie

AUGUST 5, 2024

Imagine going in for a diagnostic MRI scan and coming out with a progressive, irreversible, and potentially fatal disease. It certainly doesn't help matters that the disease has been linked to gadolinium-based contrast agents, a ubiquitous tool in the MR armamentarium. In 2006 the U.S. report of NSF in 33 dialysis patients at a St.

Disease

Disease MRI Radiologist X-ray

4 Trends in medical imaging in 2024: Breakthroughs in radiology productivity

AuntMinnie

JANUARY 30, 2024

For many, machine learning's potential is more than just talk; the power of well-trained, image-augmented AI has already been demonstrated as a useful tool for quality control, disease tracking, tumor segmentation, and making prognosis predictions.

Medical Imaging

Medical Imaging Medical Radiology Imaging

Diagnostic Imaging Brief

First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

GE HealthCare Closes MIM Software Acquisition

Trending Sources

NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

GE HealthCare Announces Agreement to Acquire MIM Software

NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

The rise of theranostics: Part 3 -- What is a theranostics center?

First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

AuntMinnie 2007: Gadolinium: A 'necessary factor' in the development of NSF?

4 Trends in medical imaging in 2024: Breakthroughs in radiology productivity

Stay Connected